| Literature DB >> 29466416 |
Einar-Jón Einarsson1,2, Mitesh Patel3, Hannes Petersen2,4, Thomas Wiebe5, Per-Anders Fransson1, Måns Magnusson1,6, Christian Moëll5.
Abstract
Chemotherapy in childhood can result in long-term neurophysiological side-effects, which could extend to visual processing, specifically the degree to which a person relies on vision to determine vertical and horizontal (visual dependency). We investigated whether adults treated with chemotherapy in childhood experience elevated visual dependency compared to controls and whether any difference is associated with the age at which subjects were treated. Visual dependency was measured in 23 subjects (mean age 25.3 years) treated in childhood with chemotherapy (CTS) for malignant, solid, non-CNS tumors. We also stratified CTS into two groups: those treated before 12 years of age and those treated from 12 years of age and older. Results were compared to 25 healthy, age-matched controls. The subjective visual horizontal (SVH) and vertical (SVV) orientations was recorded by having subjects position an illuminated rod to their perceived horizontal and vertical with and without a surrounding frame tilted clockwise and counter-clockwise 20° from vertical. There was no significant difference in rod accuracy between any CTS groups and controls without a frame. However, when assessing visual dependency using a frame, CTS in general (p = 0.006) and especially CTS treated before 12 years of age (p = 0.001) tilted the rod significantly further in the direction of the frame compared to controls. Our findings suggest that chemotherapy treatment before 12 years of age is associated with elevated visual dependency compared to controls, implying a visual bias during spatial activities. Clinicians should be aware of symptoms such as visual vertigo in adults treated with chemotherapy in childhood.Entities:
Mesh:
Year: 2018 PMID: 29466416 PMCID: PMC5821353 DOI: 10.1371/journal.pone.0193075
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Subject characteristics, diagnosis and chemotherapy details.
| Subject | Gender | Age at treatment (years) | Age at assessment (years) | Duration of treatment (weeks) | Diagnosis | Chemotherapy treatment agents |
|---|---|---|---|---|---|---|
| 1 | Female | 0.1 | 23.4 | 10 | Sacrococcygeal teratoma | Ble, Cis, Eto |
| 2 | Female | 2.5 | 15.9 | 20 | Hepatoblastoma | Adr, Cis |
| 3 | Female | 2.5 | 17.7 | 14 | Embryonal teratoma | Ble, Cis, Eto |
| 4 | Male | 2.9 | 16.4 | 35 | Ewing sarcoma | Act, Adr, Eto, Ifo, Vin |
| 5 | Female | 6.1 | 17.5 | 27 | Osteosarcoma | Adr, Cis, Met |
| 6 | Female | 8.4 | 15.5 | 46 | Osteosarcoma | Adr, Cis, Ifo, Met |
| 7 | Female | 8.6 | 30.0 | 62 | Ewing sarcoma | Act, Adr, Ble, Cyc, Met, Vin |
| 8 | Male | 8.7 | 27.7 | 58 | Ewing sarcoma | Act, Adr, Ble, Cyc, Met, Vin |
| 9 | Male | 8.9 | 21.4 | 12 | Neuroblastoma | Car, Cis, Cyc, Eto, Mel, Vin |
| 10 | Female | 9.1 | 18.5 | 8 | Immature teratoma | Ble, Cis, Eto |
| 11 | Male | 9.6 | 30.3 | 58 | Ewing sarcoma | Act, Adr, Ble, Cyc, Met, Vin |
| 12 | Male | 9.9 | 27.6 | 39 | Osteosarcoma | Act, Adr, Ble, Cis, Cyc, Met |
| 13 | Female | 10.3 | 35.8 | 58 | Immature teratoma | Act, Adr, Cyc, Vin |
| 14 | Male | 10.7 | 33.1 | 49 | Ewing sarcoma | Act, Adr, Ble, Cis, Cyc, Met, Vin |
| 15 | Female | 12.1 | 18.4 | 39 | Ewing sarcoma | Act, Adr, Cyc, Eto, Ifo, Vin |
| 16 | Female | 12.6 | 27.4 | 25 | Osteosarcoma | Adr, Cis, Met |
| 17 | Female | 14.3 | 33.9 | 29 | Osteosarcoma | Act, Adr, Ble, Cis, Cyc, Met |
| 18 | Male | 15.5 | 35.4 | 65 | Ewing sarcoma | Act, Adr, Ble, Cyc, Met, Vin |
| 19 | Male | 15.7 | 24.0 | 31 | Ewing sarcoma | Adr, Cis, Ifo, Vin |
| 20 | Male | 16.5 | 27.8 | 9 | Immature teratoma | Ble, Cis, Eto |
| 21 | Male | 16.8 | 23.7 | 76 | Ewing sarcoma | Act, Adr, Cis, Cyc, Eto, Ifo, Vin |
| 22 | Male | 16.9 | 30.9 | 27 | Osteosarcoma | Adr, Cis, Met |
| 23 | Male | 17.0 | 30.4 | 23 | Osteosarcoma | Adr, Cis, Eto, Ifo, Met |
1 Act: Actinomycin-D; Adr: Adriamycin; Ble: Bleomycin; Car: Carboplatin; Cis: Cisplatin; Cyc: Cyclophosphamide; Eto: Etoposide; Ifo: Ifosfamide; Mel: Melphalan; Met: Methotrexate; Vin: Vincristine.
Fig 1Illustration of no frame and rod & frame tests.
The subjects were instructed to position a green rod four times each in perfect horizontal or vertical directions. The rod was rotated around its centered axis, whereas the position and rotation of the frames were fixed during the assessments. The brightness of the rod and the frames were fixed. Before testing commenced it was ensured that the brightness was sufficient to allow the test subject to clearly detect the rod and frames.
Fig 2(A) Signed and (B) Absolute rod inaccuracy (mean and SEM) when the tests were performed without a frame around the rod. Positive values illustrate a CW inaccuracy and negative values illustrate a CCW inaccuracy from correct spatial orientation.
Effects of chemotherapy and orientation on rod accuracy.
| Chemotherapy | Orientation | Chemotherapy x Orientation | ||
|---|---|---|---|---|
| CTS vs controls | Signed | 0.448 [0.6] | 0.208 [1.6] | |
| Absolute | 0.310 [1.1] | 0.283 [1.2] | 0.588 [0.3] | |
| CTS_Young vs controls | Signed | 0.251 [1.4] | 0.103 [2.8] | |
| Absolute | 0.126 [2.5] | 0.436 [0.6] | 0.765 [0.1] | |
| CTS_Old vs controls | Signed | 0.954 [0.0] | 0.849 [0.0] | |
| Absolute | 0.999 [0.0] | 0.322 [1.0] | 0.539 [0.4] | |
| CTS_Young vs CTS_Old | Signed | 0.414 [0.7] | 0.268 [1.3] | |
| Absolute | 0.318 [1.0] | 0.267 [1.3] | 0.730 [0.1] | |
Repeated measures GLM ANOVA analysis of how the rod accuracy was affected by main factors “Chemotherapy” and SVH/SVV “Orientation” alone and by the main factor interaction denoted as “Chemotherapy x Orientation”. The notation “<0.001” means that the p-value is smaller than 0.001. F-values are presented in the squared parenthesis.
1 In the CTS_Young vs CTS_Old GLM ANOVA evaluation the main factor “Chemotherapy” represents the effect of receiving chemotherapy below 12 years of age (CTS_Young) vs from 12 years of age and older (CTS_Old).
Effects of chemotherapy, orientation and frame tilt on rod accuracy.
| Chemo | Orientation | Frame | Chemo x Orientation | Chemo x Frame | Orientation x Frame | Chemo x Orientationx Frame | ||
|---|---|---|---|---|---|---|---|---|
| CTS vs controls | Signed | 0.367 [0.8] | 0.701 [0.1] | 0.546 [0.4] | 0.217 [1.6] | |||
| Absolute | 0.088 [3.0] | 0.153 [2.1] | 0.780 [0.1] | 0.499 [0.5] | ||||
| CTS_Young vs controls | Signed | 0.183 [1.8] | 0.927 [0.0] | 0.488 [0.5] | 0.855 [0.0] | |||
| Absolute | 0.417 [0.7] | 0.064 [3.6] | 0.882 [0.0] | 0.360 [0.9] | ||||
| CTS_Old vs controls | Signed | 0.958 [0.0] | 0.506 [0.5] | 0.875 [0.0] | 0.229 [1.5] | |||
| Absolute | 0.365 [0.8] | 0.639 [0.2] | 0.390 [0.8] | 0.970 [0.0] | ||||
| CTS_Young vs CTS_Old | Signed | 0.460 [0.6] | 0.962 [0.0] | 0.657 [0.2] | 0.072 [3.6] | 0.145 [2.3] | ||
| Absolute | 0.068 [3.7] | 0.214 [1.6] | 0.442 [0.6] | 0.931 [0.0] | 0.465 [0.6] | |||
Repeated measures GLM ANOVA analysis of how the rod accuracy was affected by main factors “Chemotherapy” (denoted Chemo in the table), SVH/SVV “Orientation” and CW/CCW “Frame” tilt direction alone and by their main factor interactions.
Fig 3(A) Signed and (B) Absolute rod inaccuracy (mean and SEM) when the tests were performed with a frame around the rod, the frame tilted either CW or CCW. The Bonferroni corrected significance level is in the between-groups analyses set to p<0.025, though for consistency reasons p-values to the level of 0.05 are also presented in the figure.